01:04:31

PlusLive

Is Moderna Overvalued? A Look At The Economics of Vaccines

Featuring Damien Conover and Jack Farley

September 28 at 3:00PM • 64 minutes

42

1

Plus

Live

Is Moderna Overvalued? A Look At The Economics of Vaccines

Damien Conover, managing director of healthcare equity research at Morningstar, gives an update of the biotechnology stocks and the COVID-19 vaccines.

Featuring Damien Conover and Jack Farley

September 28 at 3:00PM • 64 minutes

Most companies producing COVID-19 vaccines have appreciated substantially in the past year—from new biotech companies like Moderna and BioNTech SE, who rely heavily on the vaccine for revenues, to established players like AstraZeneca and Johnson & Johnson, which have pledged to sell their vaccines on a not-for profit level. Will the momentum keep going these biotech stocks? Damien Conover, managing director of healthcare equity research at Morningstar, shares his perspective on the biotech space and also breaks down his outlook for other companies like Sanofi, Merck, and Bayer AG. Interviewed by Jack Farley, who will be taking live questions from Real Vision Plus members. Show More

Real Vision Live offers Plus and above members the opportunity to interact in real time with experts about all things related to financial markets. Features timely, in-depth analysis on what's driving price action across all asset classes. Nothing is off the table.

More Episodes

Real Vision Live offers Plus and above members the opportunity to interact in real time with experts about all things related to financial markets. Features timely, in-depth analysis on what's driving price action across all asset classes. Nothing is off the table.

More Episodes

COMMENTS

Sort By
  • Newest First
  • Oldest First
  • Top Rated
  • Most Discussed
  • Most Controversial

Access Plus Content

This content is reserved for the thousands of visionaries supporting the financial revolution. We'd love for you to join us. Interested?

See Our Plans

Already have an account? Log In